A comparative study of ESG (Environmental, Social, and Governance) disclosure across the pharmaceutical, IT, and banking industries is essential for understanding the varying impacts and challenges these sectors face in sustainability and corporate governance. Each industry operates in unique regulatory, operational, and stakeholder environments, which significantly influence their ESG priorities and reporting practices. For instance, the pharmaceutical industry is heavily scrutinized for its environmental footprint due to manufacturing processes and waste management, while IT companies focus on energy consumption and data privacy issues. Banking institutions, on the other hand, play a pivotal role in financing sustainable projects and adhering to governance norms due to their public-facing operations. By analyzing and comparing ESG disclosures, stakeholders—including investors, regulators, and consumers—can assess how these industries align with global sustainability goals. It also highlights best practices and areas for improvement, encouraging transparency and accountability. Such studies enable businesses to benchmark their performance, identify risks, and adapt strategies for long-term resilience while ensuring they meet the growing demands of socially conscious investors and regulatory frameworks.